Fisher Edwin R, Colangelo Linda, Wieand Samuel, Fisher Bernard, Wolmark Norman
National Surgical Adjuvant Breast and Bowel Project (NSABP), Pathology, Biostatistical and Headquarters Centers, Pittsburgh, Pennsylvania, USA.
Dis Colon Rectum. 2003 Aug;46(8):1021-5; discussion 1025-6. doi: 10.1007/s10350-004-7275-9.
Results of the few extant reports concerning the clinical significance of so-called "occult micrometastases" of lymph nodes of patients with Dukes A and B colorectal cancer have been variable. We examined the presumably negative nodes of a larger cohort of such patients who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trials R-01 and C-01 for the influence of what we preferably designate as nodal mini micrometastases on parameters of survival.
Mini micrometastases were detected by immunohistochemical staining of the original lymph node sections with anticytokeratin A1/A3 in a total of 241 Dukes A and B patients with rectal and 158 with colonic cancers. Their frequency, as well as that of nuclear and histologic grades, and an estimation of their relationship to relative risks were correlated with overall and recurrence-free survival by univariate and multivariate analyses.
Nodal mini micrometastases were detected in 73 of 399 (18.3 percent) patients of this cohort. They failed to exhibit any significant relationship to overall or recurrence-free survival. No association between the assessments of tumor differentiation and mini micrometastases was found. Nuclear and histologic grades also failed to further discriminate overall or recurrence-free survival in patients with A or B stages of colonic or rectal cancers in this cohort.
The immunohistochemical demonstration of nodal mini micrometastases failed to discriminate high- and low-risk groups of patients with colorectal cancer who were designated as being node-negative after routine pathologic examination.
关于 Dukes A 期和 B 期结直肠癌患者淋巴结所谓“隐匿性微转移”的临床意义,现存的少数报告结果不一。我们检查了参加国家外科辅助乳腺和肠道项目临床试验 R - 01 和 C - 01 的大量此类患者的推测为阴性的淋巴结,以研究我们更倾向称为淋巴结微小转移对生存参数的影响。
对总共 241 例 Dukes A 期和 B 期直肠癌患者及 158 例结肠癌患者的原始淋巴结切片进行抗细胞角蛋白 A1/A3 免疫组化染色,以检测微小转移。通过单因素和多因素分析,将其频率、核分级和组织学分级以及它们与相对风险的关系与总生存和无复发生存相关联。
在该队列的 399 例患者中的 73 例(18.3%)检测到淋巴结微小转移。它们与总生存或无复发生存均无显著关系。未发现肿瘤分化评估与微小转移之间存在关联。在该队列中,核分级和组织学分级也未能进一步区分结肠癌或直肠癌 A 期或 B 期患者的总生存或无复发生存。
淋巴结微小转移的免疫组化显示未能区分在常规病理检查后被指定为淋巴结阴性的结直肠癌患者的高风险和低风险组。